The constitutive activation of HER3 signalling in TKI-resistant lung cancers can also be mediated through the amplification of MET, recently identified in certain TKI-resistant subclones of lung cancer cells (Engelman et al, 2007) (Figure 1). The gene discussed is MET; the disease is lung carcinoma.